{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-+1+%28GLP-1%29+infusion",
    "query": {
      "intervention": "Glucagon-Like Peptide- 1 (GLP-1) infusion"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-+1+%28GLP-1%29+infusion&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T07:05:19.026Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01162499",
      "title": "Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postprandial Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Exendin-(9-39)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Diva De Leon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 7,
      "start_date": "2010-04",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-10-23",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01162499"
    },
    {
      "nct_id": "NCT01729299",
      "title": "Ghrelin Effect on Beta Cell Function in Health and Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Exendin (9-39)",
          "type": "DRUG"
        },
        {
          "name": "acyl ghrelin",
          "type": "DRUG"
        },
        {
          "name": "saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Dalessio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2013-04",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2013-04-04",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01729299"
    },
    {
      "nct_id": "NCT04347252",
      "title": "Glucagon Regulation of Glucose Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Secretion"
      ],
      "interventions": [
        {
          "name": "Glucagon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David D'Alessio, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2019-09-24",
      "completion_date": "2021-04-16",
      "has_results": false,
      "last_update_posted_date": "2021-05-14",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04347252"
    },
    {
      "nct_id": "NCT00882492",
      "title": "GLP 1 for Intraoperative Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperglycemia",
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "GLP 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "normal saline solution placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2008-12",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2012-02-16",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00882492"
    },
    {
      "nct_id": "NCT00882050",
      "title": "Intravenous Exenatide (Byetta) During Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Euglycemia",
        "Hypoglycemia",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Exenatide 0.27 ng/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Exenatide 0.41 ng/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2009-03",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2022-01-21",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00882050"
    },
    {
      "nct_id": "NCT05375968",
      "title": "Splanchnic Venous Capacitance in Postural Tachycardia Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postural Tachycardia Syndrome (POTS)"
      ],
      "interventions": [
        {
          "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2",
          "type": "DRUG"
        },
        {
          "name": "Compare change is SVC and SMA flow due to saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-02-25",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375968"
    },
    {
      "nct_id": "NCT04466566",
      "title": "A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Saline",
          "type": "OTHER"
        },
        {
          "name": "Exendin-9,39",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Adrian Vella",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2022-10-17",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04466566"
    },
    {
      "nct_id": "NCT00798590",
      "title": "The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Critically Ill",
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Glucagon-Like Peptide-1",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2008-12",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798590"
    },
    {
      "nct_id": "NCT00835328",
      "title": "Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "Exendin (9-39)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Diva De Leon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "Up to 12 Months"
      },
      "enrollment_count": 14,
      "start_date": "2009-08-26",
      "completion_date": "2017-01-28",
      "has_results": true,
      "last_update_posted_date": "2020-06-01",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00835328"
    },
    {
      "nct_id": "NCT01413542",
      "title": "Pharmacogenetics of Ace Inhibitor-Associated Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension",
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Sitagliptin (DPP4 inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Substance P,",
          "type": "DRUG"
        },
        {
          "name": "bradykinin",
          "type": "DRUG"
        },
        {
          "name": "enalaprilat (ACE inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide 1",
          "type": "DRUG"
        },
        {
          "name": "brain natriuretic peptide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2011-11",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-10-09T07:05:19.026Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01413542"
    }
  ]
}